NASDAQ:APVO - Aptevo Therapeutics Stock Price, Forecast & News

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Aptevo Therapeutics Inc (NASDAQ:APVO) issued its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.01. The biotechnology company had revenue of $9.01 million for the quarter, compared to analyst estimates of $8.05 million. Aptevo Therapeutics had a negative net margin of 156.03% and a negative return on equity of 171.99%. View Aptevo Therapeutics' Earnings History.

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aptevo Therapeutics.

2 analysts have issued 1 year target prices for Aptevo Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Aptevo Therapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 375.1% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.

News headlines about APVO stock have trended extremely negative on Wednesday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptevo Therapeutics earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Aptevo Therapeutics.

Some companies that are related to Aptevo Therapeutics include CELYAD SA/ADR (CYAD), Millendo Therapeutics (MLND), Marinus Pharmaceuticals (MRNS), Oncolytics Biotech (ONCY), Scpharmaceuticals (SCPH), CV Sciences (CVSI), Otonomy (OTIC), TFF Pharmaceuticals (TFFP), Aquestive Therapeutics (AQST), Cyclerion Therapeutics (CYCN), AVEO Pharmaceuticals (AVEO), Stealth BioTherapeutics (MITO), Bellicum Pharmaceuticals (BLCM), Sesen Bio (SESN) and Enlivex Therapeutics (ENLV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), AbbVie (ABBV), Alibaba Group (BABA), AVEO Pharmaceuticals (AVEO), BIOLINERX LTD/S (BLRX) and Exelixis (EXEL).

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APVO stock can currently be purchased for approximately $0.63.

Aptevo Therapeutics has a market capitalization of $28.59 million and generates $23.07 million in revenue each year. The biotechnology company earns $-53,690,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.View Additional Information About Aptevo Therapeutics.

The official website for Aptevo Therapeutics is http://www.aptevotherapeutics.com/.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]